Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC.
It has strategic collaborations with F.
Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | -0.35 Increased by +32.69% | -0.38 Increased by +7.89% |
| Aug 1, 24 | -0.26 Increased by +64.38% | -0.37 Increased by +29.73% |
| May 8, 24 | -0.41 Increased by +42.25% | -0.35 Decreased by -17.14% |
| Feb 22, 24 | -0.70 Increased by +9.09% | -0.68 Decreased by -2.94% |
| Nov 1, 23 | -0.52 Increased by +20.00% | -0.66 Increased by +21.21% |
| Aug 8, 23 | -0.73 Decreased by -30.36% | -0.69 Decreased by -5.80% |
| May 4, 23 | -0.71 Decreased by -9.23% | -0.75 Increased by +5.33% |
| Feb 23, 23 | -0.77 Decreased by -148.39% | -0.74 Decreased by -4.05% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 15.36 M Increased by +38.75% | -24.67 M Increased by +8.77% | Decreased by -160.57% Increased by +34.25% |
| Jun 30, 24 | 12.01 M Increased by +350.68% | -17.72 M Increased by +50.68% | Decreased by -147.56% Increased by +89.06% |
| Mar 31, 24 | 3.04 M Decreased by -19.15% | -28.36 M Increased by +16.43% | Decreased by -933.23% Decreased by -3.37% |
| Dec 31, 23 | 3.26 M Increased by +14.26% | -34.75 M Increased by +3.67% | Decreased by -1.07 K% Increased by +15.69% |
| Sep 30, 23 | 11.07 M Increased by +63.93% | -27.04 M Increased by +13.97% | Decreased by -244.19% Increased by +47.52% |
| Jun 30, 23 | 2.66 M Decreased by -80.74% | -35.92 M Decreased by -30.91% | Decreased by -1.35 K% Decreased by -579.81% |
| Mar 31, 23 | 3.76 M Decreased by -50.89% | -33.94 M Decreased by -6.49% | Decreased by -902.85% Decreased by -116.82% |
| Dec 31, 22 | 2.85 M Decreased by -85.79% | -36.08 M Decreased by -130.41% | Decreased by -1.26 K% Decreased by -1.52 K% |